Thousands of women in England will be able to get breast cancer pills: what is known
Kyiv • UNN
The National Health Service of England must introduce rapid genetic testing to ensure that those who are eligible receive the drug without further delay.

In England and Wales, thousands of women with advanced breast cancer will be able to receive tablets for the disease from the National Health Service if the drug regulatory authority approves the distribution of the drug. This is reported by UNN with reference to TheGuardian.
Details
The drug Truqap, manufactured by AstraZeneca, blocks an abnormal protein molecule AKT, which causes cancer cells to multiply and helps slow or stop the spread of the disease. It is suitable for tumors of patients with mutations or changes in the PIK3CA, AKT1 or PTEN genes. They are found in approximately half of patients with this form of breast cancer.
The initial rejection of the tablets led to treatment delays. This happens all too often, and urgent action needs to be taken to ensure that breast cancer drugs are quickly approved so that they can be quickly available to those who need them
She believes that the National Health Service of England should introduce rapid genetic testing to ensure that those who are eligible receive the drug without further delay. The Scottish Medicines Consortium, she believes, should also immediately consider this treatment so that it is available to all who need it in the UK.
Research results
Research results show that Truqap (capivasertib) in combination with fulvestrant hormone therapy increased the time to cancer worsening by approximately 4.2 months.
The Institute of Cancer Research (ICR) in London welcomed the approval of the drug, which has changed the rules of the game after decades of research.
Approval in Nice means that thousands of NHS patients with advanced breast cancer with these specific biomarkers can now receive this innovative targeted treatment to prevent cancer from progressing for longer
I am delighted to celebrate this landmark moment and see capivasertib become available in the NHS (England - ed.). It is extremely gratifying that years of collaboration have contributed to the creation of this new anti-cancer drug